The clinical development of aurora kinase inhibitors in acute myeloid leukemia

Kevin R. Kelly; Ciara L. Freeman; Francis J. Giles

doi:10.1007/978-1-4939-1393-0_20

The clinical development of aurora kinase inhibitors in acute myeloid leukemia

Kevin R. Kelly, Ciara L. Freeman, Francis J. Giles

Research output: Chapter in Book or Conference Publication/Proceeding › Chapter › peer-review

1 Citation (Scopus)

Abstract

The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition in the treatment of acute myeloid leukemia (AML). Moreover, early-phase clinical studies on AML have shown that these agents have therapeutic efficacy both alone and in combination with chemotherapy.

Original language	English
Title of host publication	Targeted Therapy of Acute Myeloid Leukemi
Publisher	Springer New York
Pages	391-407
Number of pages	17
ISBN (Electronic)	9781493913930
ISBN (Print)	9781493913923
DOIs	https://doi.org/10.1007/978-1-4939-1393-0_20
Publication status	Published - 1 Jan 2015
Externally published	Yes

Keywords

Acute myeloid leukemia
Aurora kinases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-4939-1393-0_20

Cite this

@inbook{713f60f19e8745afa566192344943652,

title = "The clinical development of aurora kinase inhibitors in acute myeloid leukemia",

abstract = "The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition in the treatment of acute myeloid leukemia (AML). Moreover, early-phase clinical studies on AML have shown that these agents have therapeutic efficacy both alone and in combination with chemotherapy.",

keywords = "Acute myeloid leukemia, Aurora kinases",

author = "Kelly, {Kevin R.} and Freeman, {Ciara L.} and Giles, {Francis J.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-1393-0_20",

language = "English",

isbn = "9781493913923",

pages = "391--407",

booktitle = "Targeted Therapy of Acute Myeloid Leukemi",

publisher = "Springer New York",

}

TY - CHAP

T1 - The clinical development of aurora kinase inhibitors in acute myeloid leukemia

AU - Kelly, Kevin R.

AU - Freeman, Ciara L.

AU - Giles, Francis J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition in the treatment of acute myeloid leukemia (AML). Moreover, early-phase clinical studies on AML have shown that these agents have therapeutic efficacy both alone and in combination with chemotherapy.

AB - The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition in the treatment of acute myeloid leukemia (AML). Moreover, early-phase clinical studies on AML have shown that these agents have therapeutic efficacy both alone and in combination with chemotherapy.

KW - Acute myeloid leukemia

KW - Aurora kinases

UR - http://www.scopus.com/inward/record.url?scp=84944570150&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1393-0_20

DO - 10.1007/978-1-4939-1393-0_20

M3 - Chapter

AN - SCOPUS:84944570150

SN - 9781493913923

SP - 391

EP - 407

BT - Targeted Therapy of Acute Myeloid Leukemi

PB - Springer New York

ER -

The clinical development of aurora kinase inhibitors in acute myeloid leukemia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this